191 related articles for article (PubMed ID: 15539105)
1. Should albuminuria be a therapeutic target in patients with hypertension and diabetes?
de Zeeuw D
Am J Hypertens; 2004 Nov; 17(11 Pt 2):11S-15S; quiz A2-4. PubMed ID: 15539105
[TBL] [Abstract][Full Text] [Related]
2. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
de Zeeuw D
Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
[TBL] [Abstract][Full Text] [Related]
3. Improving microvascular outcomes in patients with diabetes through management of hypertension.
McGill JB
Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
[TBL] [Abstract][Full Text] [Related]
4. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
[TBL] [Abstract][Full Text] [Related]
5. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Circulation; 2004 Aug; 110(8):921-7. PubMed ID: 15302780
[TBL] [Abstract][Full Text] [Related]
6. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Eijkelkamp WB; Zhang Z; Remuzzi G; Parving HH; Cooper ME; Keane WF; Shahinfar S; Gleim GW; Weir MR; Brenner BM; de Zeeuw D
J Am Soc Nephrol; 2007 May; 18(5):1540-6. PubMed ID: 17409317
[TBL] [Abstract][Full Text] [Related]
7. Renal protection in diabetic patients: benefits of a first-line combination of perindopril-indapamide (Preterax).
Ruilope LM; Segura J
J Hypertens Suppl; 2006 May; 24(3):S9-12. PubMed ID: 16723864
[TBL] [Abstract][Full Text] [Related]
8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
9. [Hypertension in patients with diabetes].
Poulsen PL; Hansen KW; Gaede PH; Rossing P
Ugeskr Laeger; 2009 Jun; 171(24):2031-4. PubMed ID: 19523370
[TBL] [Abstract][Full Text] [Related]
10. Cardiac, renal and vascular complications in the diabetic patient.
Zanchetti A
J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S21-4. PubMed ID: 17199215
[TBL] [Abstract][Full Text] [Related]
11. Lessons learned from recent clinical trials in hypertensive diabetics: what's good for the kidney is good for the heart and brain.
Toto RD
Am J Hypertens; 2004 Nov; 17(11 Pt 2):7S-10S; quiz A2-4. PubMed ID: 15539108
[TBL] [Abstract][Full Text] [Related]
12. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
Agha A; Bashir K; Anwar E
Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
[TBL] [Abstract][Full Text] [Related]
13. Diabetic nephropathy.
Ritz E
Saudi J Kidney Dis Transpl; 2006 Dec; 17(4):481-90. PubMed ID: 17186681
[TBL] [Abstract][Full Text] [Related]
14. The bedtime administration of doxazosin controls morning hypertension and albuminuria in patients with type-2 diabetes: evaluation using home-based blood pressure measurements.
Kamoi K; Ikarashi T
Clin Exp Hypertens; 2005 May; 27(4):369-76. PubMed ID: 15921073
[TBL] [Abstract][Full Text] [Related]
15. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
Yamout H; Lazich I; Bakris GL
Adv Chronic Kidney Dis; 2014 May; 21(3):281-6. PubMed ID: 24780456
[TBL] [Abstract][Full Text] [Related]
16. [Microalbuminuria in diabetes: setting the points for treatment].
Lehnert H; Klose S; Lobmann R; Zehnder D
MMW Fortschr Med; 2006 May; 148(21):28-30, 33; quiz 34. PubMed ID: 16796185
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for development and progression of diabetic kidney disease and treatment patterns among diabetic siblings of patients with diabetic kidney disease.
Bleyer AJ; Sedor JR; Freedman BI; O'Brien A; Russell GB; Graley J; Schelling JR
Am J Kidney Dis; 2008 Jan; 51(1):29-37. PubMed ID: 18155530
[TBL] [Abstract][Full Text] [Related]
18. The future of antihypertensive treatment.
Israili ZH; Hernández-Hernández R; Valasco M
Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
[TBL] [Abstract][Full Text] [Related]
19. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications.
Cooper ME
Am J Hypertens; 2004 Nov; 17(11 Pt 2):16S-20S; quiz A2-4. PubMed ID: 15539106
[TBL] [Abstract][Full Text] [Related]
20. Reviewing the benefits of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy--are they drug specific or class specific?
Burgess E
Can J Cardiol; 2010 Dec; 26 Suppl E():15E-19E. PubMed ID: 21620286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
